Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice

Both the PC-3 and the TSU-PR1 prostate tumor models were found to be satisfactory for chemotherapeutic investigations in ICR-SCID mice. The 30 to 60 mg fragments implanted took in all mice (as judged by 100% takes in the controls of all experiments as well as the passage mice). The tumor volume doub...

Full description

Saved in:
Bibliographic Details
Published in:Investigational new drugs 1997-01, Vol.15 (2), p.99-108
Main Authors: POLIN, L, VALERIOTE, F, GOLAKOTI, T, PATTERSON, G, MOORE, R, CORBETT, T. H, WHITE, K, PANCHAPOR, C, PUGH, S, KNIGHT, J, LORUSSO, P, HUSSAIN, M, LIVERSIDGE, E, PELTIER, N
Format: Article
Language:English
Subjects:
Aged
Animals
Antineoplastic agents
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Chemotherapy
Chromosomes
Depsipeptides
Drugs, Investigational - therapeutic use
Female
Granulocytes
Humans
Lactams - therapeutic use
Lactones - therapeutic use
Male
Medical sciences
Metastasis
Mice
Mice, Nude
Mice, SCID
Middle Aged
Nanoparticles
Paclitaxel - therapeutic use
Pharmacology. Drug treatments
Piperazines - therapeutic use
Prostate cancer
Prostatic Neoplasms - drug therapy
Toxicity
Transplants & implants
Tumors
Vinblastine - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Both the PC-3 and the TSU-PR1 prostate tumor models were found to be satisfactory for chemotherapeutic investigations in ICR-SCID mice. The 30 to 60 mg fragments implanted took in all mice (as judged by 100% takes in the controls of all experiments as well as the passage mice). The tumor volume doubling time was 4.0 days for PC-3 and 2.5 days for TSU-PR1. Nine agents were evaluated IV against early stage subcutaneous PC-3 tumors, with Nano-piposulfan being the only agent highly active (4.9 log kill). Three other agents were moderately active: Taxol (1.5 log kill), Cryptophycin-8 (1.6 log kill), Vinblastine (1.0 log kill). Five agents were inactive: VP-16, Adriamycin, CisDDPt, 5-FUra, and Cyclophosphamide. Ten agents were evaluated IV against early stage subcutaneous TSU-PR1 tumors. Three agents were highly active, producing > 6 log kill and cures: Taxol (5/5 cures), Cryptophycin-8 (5/5 cures), Vinblastine (2/4 cures). Two other agents were moderately active: Nano-piposulfan (1.2 log kill), and Cyclophosphamide (1.1 log kill). Five agents were inactive: VP-16, Adriamycin, CisDDPt, 5-FUra, and BCNU. In part, activity was determined by the ability of the SCID mice to tolerate meaningful dosages of the agents. Agents producing granulocyte toxicity (e.g., Adriamycin) were poorly tolerated and appeared less active than expected. Vinblastine, producing little or no granulocyte toxicity was very well tolerated and appeared to be more active than expected.
ISSN:0167-6997
1573-0646
DOI:10.1023/A:1005856605726